Affimed (NASDAQ:AFMD) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Affimed (NASDAQ:AFMD) in a research report sent to investors on Monday morning, Benzinga reports.

AFMD has been the topic of several other reports. HC Wainwright restated a buy rating and issued a $10.00 price target on shares of Affimed in a research report on Friday. Laidlaw increased their target price on shares of Affimed from $15.00 to $25.00 and gave the stock a buy rating in a research report on Thursday, June 13th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $32.50.

Affimed Stock Up 4.3 %

Shares of NASDAQ:AFMD opened at $3.92 on Monday. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.13. Affimed has a 1 year low of $2.23 and a 1 year high of $8.95. The business has a fifty day simple moving average of $4.61 and a 200 day simple moving average of $5.22.

Affimed (NASDAQ:AFMD) last announced its earnings results on Wednesday, June 12th. The biopharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.73) by $0.35. The firm had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $1.76 million. Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%. On average, equities research analysts expect that Affimed will post -3.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Choreo LLC bought a new position in Affimed in the second quarter valued at approximately $54,000. Vestal Point Capital LP acquired a new stake in Affimed during the 4th quarter worth approximately $341,000. Finally, BNP Paribas Financial Markets lifted its holdings in Affimed by 39.9% during the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after purchasing an additional 163,162 shares during the last quarter. 30.82% of the stock is currently owned by institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.